News | February 11, 2015

Image-Guided Pre-Surgery Radiation Significantly Reduces Long-Term Negative Impact in Certain Cancers

New standard of care targeted toward soft tissue cancers in the extremities

February 11, 2015 — Using advanced imaging technology to more precisely target radiation beams to treat soft tissue cancers (sarcomas) in the extremities significantly reduces long term side effects without effecting survival rates, according to research results published online in the Journal of Clinical Oncology.

The findings should establish a new standard of care for soft tissue sarcomas. “This study proves that we are able to use this modern technology  — image-guided radiotherapy — to irradiate smaller target volumes  and reduce long-term side effects in extremity sarcoma patients compared with conventional radiotherapy,” says Dian Wang, M.D., the lead author of the paper. He is professor of radiation oncology at Rush University Medical Center and chair of the NRG Oncology Sarcoma Working Group.

“This is one of few successful multi-institutional studies on localized sarcoma in almost a decade,” Wang said “It should provide oncologists with validation and evidence of this new radiotherapy approach that takes full advantage of rapidly developing technologies. The absence of marginal-field recurrence and favorable toxicity profiles suggest that parameters used in this study are appropriate for preoperative image-guided radiotherapy of extremity sarcoma,” Wang added.

The study results came from a multi-year, multi-institution phase 2 clinical trial conducted by the Radiation Therapy Oncology Group (RTOG), now conducting research as NRG Oncology.

The RTOG 0630 trial studied more than 100 patients with extremity-based soft tissue sarcomas (STS) who received pre-surgical radiation delivered to a substantially smaller area than typically targeted when treating this type of cancer. Prior to tumor removal surgery, a series of daily pre-treatment images of the tumor were digitally integrated with previous scans to determine a custom-tailored radiation dose that minimized exposure to adjacent normal tissue. Assessments two years later showed that long-term side effects were 10.5 percent, significantly fewer than the 37 percent of patients in a previous study who received radiation to a larger target area.

The trial was conducted over three years at 18 medical centers across the country.

For more information: www.nrgoncology.org

Related Content

ZON-PTC in Clinical Use With RayStation 8B and Hyperscan
News | Treatment Planning | March 19, 2019
Zuid-Oost Nederland Protonen Therapie Centrum (ZON-PTC), Maastricht, Netherlands, recently treated its first patient...
What to Expect from the Proton Therapy Market in 2019-2020
News | Proton Therapy | March 13, 2019
The number of new particle therapy rooms ordered worldwide dropped by almost 20 percent in 2018, according to a new...
Mississippi Cancer Center Combines RayStation and TomoTherapy for Prostate Cancer Case
News | Treatment Planning | March 08, 2019
Anderson Regional Cancer Center in Meridian, Miss., has treated its first patient using the combination of RaySearch's...
Videos | Proton Therapy | March 01, 2019
ITN Associate Editor Jeff Zagoudis speaks with Mark Pankuch, Ph.D., director of physics and dosimetry at the...
Videos | Proton Therapy | February 28, 2019
ITN Associate Editor Jeff Zagoudis speaks with ...
360_NW_Proton_Center_Gantry_Room_Back_THUMBNAIL
360 Photos | 360 View Photos | February 28, 2019
This is a 360 photo view behind the gantry room at the ...
360_NW_Proton_Center_Inclined_Room_THUMBNAIL
360 Photos | 360 View Photos | February 28, 2019
This is a 360 view of Treatment Room 3 (of 4) at the N...
NW Proton Center Gantry Room Front
360 Photos | 360 View Photos | February 27, 2019
This is a 360 photo view inside the gantry room at the...
Videos | Proton Therapy | February 26, 2019
ITN Associate Editor Jeff Zagoudis speaks with ...